Skip to main content

PerkinElmer s Q2 Revenues Inch Up 3 Percent as Income Surges 39 Percent

NEW YORK, July 27 (GenomeWeb News) - PerkinElmer yesterday reported slightly increased revenues and a boost in earnings for the second quarter of 2005.


Revenues for the quarter totaled $425.5 million, representing a 3-percent increase over last year's revenues of $412.1 million during the same period. PE's life and analytical sciences unit had $270.8 million in revenues, up 5 percent from revenues of $257.9 million during the same period last year. This growth was primarily driven by PE's genetic screening, service, and environmental businesses.


Research and development expenses were $22.9 million, up slightly from $21.5 million during the same quarter last year.


The company's net income for the quarter was $28.9 million, or $.22 per share, up from last year's $20.8 million, or $.16 per share, during the same period. This quarter's earnings included both a $14.3 million benefit from provisions for income taxes and a loss of $5.2 million from discontinued operations.


As of July 3, PerkinElmer had $158.7 million in cash and cash equivalents.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.